Target

PCSK9

Proprotein convertase subtilisin/kexin type 9

43open trials
78trials in total
363publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
31 Jan 2027· PHASE4 · NOT_YET_RECRUITING· CTGOV
Trial
Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial Hypercholesterolemia
20 Jan 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque Remodeling
1 Jan 2027· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publication
PCSK9-Targeting Therapies and Mortality: A Systematic Review and Meta-Analysis of Randomized Trials.
2 Nov 2026· European journal of preventive cardiology· PUBMED
Publication
Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
1 Nov 2026· Endocrinology, diabetes & metabolism· PUBMED
Publication
Impact of Evolocumab on LDL-Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta-Analysis.
1 Nov 2026· Endocrinology, diabetes & metabolism· PUBMED
Publication
Achieving Risk-Specific Absolute LDL-C Threshold with PCSK9 Inhibitors: A Real-World, Single-Center Analysis.
26 Oct 2026· Romanian journal of internal medicine = Revue roumaine de medecine interne· PUBMED
Publication
Safety of low lipoprotein(a) levels: the FOURIER trial.
26 Oct 2026· European heart journal· PUBMED
Publication
PCSK9 drives acquired resistance to anti-PD-1 immunotherapy through cystine metabolic reprogramming in lung cancer.
20 Oct 2026· Journal for immunotherapy of cancer· PUBMED
Trial
Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma
19 Oct 2026· NA · RECRUITING· CTGOV
Publication
Impact of baseline LDL-C and Lp(a) levels on PCSK9-targeting therapy efficacy in subjects with familial hypercholesterolemia: real-world data from a tertiary lipid center.
15 Oct 2026· Nutrition, metabolism, and cardiovascular diseases : NMCD· PUBMED
Publication
Efficacy and safety of PCSK9 inhibitors combined with statins in acute ischemic stroke: a systematic review and meta-analysis.
8 Oct 2026· Journal of neurology· PUBMED
Publication
A PD-L1 Nanobody-Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC-I.
6 Oct 2026· Exploration (Beijing, China)· PUBMED
Publication
Healthy-Adherer Bias May Confound the Association Between PCSK9 Inhibitors and Incident Heart Failure.
5 Oct 2026· QJM : monthly journal of the Association of Physicians· PUBMED
Publication
Confounding by Indication and Outcome Ascertainment in the Reported Cardioprotective Effect of PCSK9 Inhibitors on Incident Heart Failure.
5 Oct 2026· QJM : monthly journal of the Association of Physicians· PUBMED
Publication
Proprotein Convertase Subtilisin/Kexin Type 9: From Biology to Therapeutic Targeting in Cardiovascular Disease.
1 Oct 2026· European journal of clinical investigation· PUBMED
Publication
[Evolocumab (Repatha®) : new evidence across the continuum of atherosclerotic cardiovascular disease].
1 Oct 2026· Revue medicale de Liege· PUBMED
Publication
Levonorgestrel-ethinyl estradiol impairs hepatic lipid clearance to induce hypercholesterolemia via PCSK9-mediated LDLR and CD36 dysregulation.
30 Sept 2026· Toxicology and applied pharmacology· PUBMED
Publication
Restores Aβ Clearance by Overcoming PCSK9-LRP1 Dysregulation and TRIB3-Mediated Autophagy Blockade in Alzheimer's Disease.
29 Sept 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
Exploratory evidence of a slower eGFR decline in patients at high risk of CKD progression treated with PCSK9 inhibitors.
26 Sept 2026· Journal of nephrology· PUBMED
Publication
Targeting the PCSK9-PR-IL-17 axis for psoriasis therapy.
25 Sept 2026· Frontiers in pharmacology· PUBMED
Publication
Signaling Demand with Cost-Effectiveness Analysis: A Case Study of PCSK9 Inhibitors.
25 Sept 2026· Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research· PUBMED
Publication
Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia.
25 Sept 2026· The Annals of pharmacotherapy· PUBMED
Trial
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
20 Sept 2026· PHASE2 · RECRUITING· CTGOV
Publication
Real-World Effectiveness of Evolocumab in Reducing Major Adverse Cardiovascular Events: A Cohort Study.
18 Sept 2026· Journal of the American Heart Association· PUBMED
Publication
PCSK9 Inhibition Attenuates Renal Oxidative Stress and Lipotoxicity in Diabetic Kidney Disease in Association with AMPK Activation.
17 Sept 2026· Antioxidants (Basel, Switzerland)· PUBMED
Publication
Familial Hypercholesterolemia.
15 Sept 2026· Methodist DeBakey cardiovascular journal· PUBMED
Publication
Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.
15 Sept 2026· Expert opinion on pharmacotherapy· PUBMED
Publication
PCSK9 Inhibitors and Risk of Aortic Stenosis in Atherosclerotic Cardiovascular Disease.
11 Sept 2026· JACC. Advances· PUBMED
Publication
Circulating PCSK9: A new frontier in cancer risk stratification for obese diabetics.
11 Sept 2026· Oncology letters· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error